Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Inlyta is a prescription kinase inhibitor containing axitinib. It is indicated with avelumab or pembrolizumab for first-line treatment of advanced renal cell carcinoma. It is also used alone for advanced renal cell carcinoma after failure of one prior systemic therapy.
read more about inlyta ...Axitinib inhibits vascular endothelial growth factor receptors 1, 2, and 3. Blocking these receptors reduces VEGF-driven blood vessel growth and related tumor signaling in susceptible renal cell carcinoma.
Inlyta is used in adults with advanced renal cell carcinoma. First-line regimens combine axitinib with avelumab or pembrolizumab. Single-agent treatment is used after failure of one prior systemic regimen.
The recommended starting dose is 5 mg by mouth twice daily about 12 hours apart with or without food. The same starting axitinib dose is used with avelumab or pembrolizumab. Dose increases, reductions, or interruptions depend on tolerability, blood pressure, adverse reactions, interacting medicines, and liver function.
Serious concerns include high blood pressure, arterial and venous thromboembolic events, hemorrhage, heart failure, gastrointestinal perforation or fistula, thyroid dysfunction, impaired wound healing, reversible posterior leukoencephalopathy syndrome, proteinuria, liver toxicity, major cardiovascular events with avelumab, and fetal harm.
Inlyta treats advanced renal cell carcinoma in specified first-line combination regimens or as single-agent therapy after one prior systemic regimen fails.
The recommended starting dose is 5 mg twice daily about 12 hours apart.
Yes. High blood pressure and hypertensive crisis have occurred during treatment.
Current labeling directs withholding Inlyta for at least two days before elective surgery and for at least two weeks after major surgery until adequate wound healing.
Axitinib. https://www.cancer.gov/about-cancer/treatment/drugs/axitinib. Date Accessed October 5, 2026.
Axitinib: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a612017.html. Date Accessed October 5, 2026.
Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. https://pubmed.ncbi.nlm.nih.gov/22056247/. Date Accessed October 5, 2026.
FDA Approves Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma. Date Accessed October 5, 2026.
INLYTA (Axitinib) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a903e31-936e-4ed7-8a59-59f32374f338. Date Accessed October 5, 2026.